NFlection Therapeutics’ NFX-179 Gel Demonstrates Safety and Significant Reduction in p-ERK, a Key Biomarker Driving Neurofibroma Tumor Growth, in Positive Data From a 28-Day Phase 2a Clinical Trial
– Trial designed to study 0.05%, 0.15% and 0.5% NFX-179 Gel in subjects with cutaneous neurofibromatosis type 1 (NF1) – NFX-179 Gel was well tolerated, with a safety profile similar to placebo (vehicle) – Primary endpoint achieved: NFX-179 Gel showed a dose-dependent suppression of phosphorylated ERK (p-ERK) in cutaneous neurofibroma (cNF) tumors, suppressing p-ERK by […]
